| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Cereblon
CRBN (cereblon), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a cereblon-binding ligand, Thalidomide-5,6-F itself has no intrinsic degradation activity. Its function is to bind to CRBN and recruit the E3 ubiquitin ligase complex. When conjugated to a target protein ligand via a linker, the resulting PROTAC can facilitate ubiquitination and degradation of the target protein. |
| ln Vivo |
No specific in vivo activity has been reported for this ligand alone; its in vivo degradation effects are observed only after conjugation with a target protein ligand to form a complete PROTAC molecule.
|
| Enzyme Assay |
N/A; as a ligand, its binding affinity to cereblon is typically determined using biophysical methods such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) as part of the validation of the final PROTAC construct. The compound is used as a synthetic intermediate rather than in isolated enzyme assays.
|
| Cell Assay |
N/A; this ligand is not evaluated alone in cell-based assays but is used as a building block to construct cereblon-recruiting PROTACs for cellular degradation studies. In a typical cellular assay, a complete PROTAC synthesized from this ligand is incubated with target-expressing cells for 4-24 hours, after which target protein levels are measured by Western blotting to determine the DC50.
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand alone. In vivo efficacy studies would be conducted using the complete PROTAC molecule synthesized from this building block.
|
| ADME/Pharmacokinetics |
The compound has a molecular formula of C13H9F2N2O4, a molecular weight of 295.22, and a purity of ≥98% (HPLC). It is typically stored as a powder at -20degC for up to 3 years or in a solvent at -80degC for 6 months. The product requires protection from light during transportation and storage.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not intended for human or veterinary use. Standard chemical safety precautions should be followed during handling. The compound should be stored in a sealed and protected environment (e.g., under nitrogen), away from moisture.
|
| References | |
| Additional Infomation |
The difluorinated thalidomide analog is used to modulate the binding properties to cereblon, potentially altering the degradation profile and neo-substrate selectivity of PROTAC molecules. This compound serves as a valuable building block for exploring structure-activity relationships in PROTAC design and targeted protein degradation research.
|
| Molecular Formula |
C13H8F2N2O4
|
|---|---|
| Molecular Weight |
294.21
|
| Exact Mass |
294.045
|
| CAS # |
1496997-41-1
|
| PubChem CID |
65968512
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
534.6±50.0 °C at 760 mmHg
|
| Flash Point |
277.1±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
0.55
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
510
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=C(C([H])=C2C(=C1[H])C(N(C2=O)C1([H])C(N([H])C(C([H])([H])C1([H])[H])=O)=O)=O)F
|
| InChi Key |
AGHXYRKTAZEQQW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H8F2N2O4/c14-7-3-5-6(4-8(7)15)13(21)17(12(5)20)9-1-2-10(18)16-11(9)19/h3-4,9H,1-2H2,(H,16,18,19)
|
| Chemical Name |
2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindole-1,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~33.33 mg/mL (~113.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3989 mL | 16.9947 mL | 33.9893 mL | |
| 5 mM | 0.6798 mL | 3.3989 mL | 6.7979 mL | |
| 10 mM | 0.3399 mL | 1.6995 mL | 3.3989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
